surpass tirzepatide SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized Diabetes Distilled: SURPASS-CVOT – Tirzepatide

In October 2025, Rybelsus also received FDA approval to reduce the risk of major adverse cardiovascular risks in adults with type 2 diabetes

95% CI, 0.511.00) and all-cause mortality (adjusted pooled HR, 0.68

Computational chemistry in toxinomimicry The path forward should entail, at least in part, a much deeper involvement of computational chemistry

However, patients should be monitored by a healthcare provider during treatment to ensure the therapy's safety and effectiveness

Medically necessary physical, occupational, and speech therapy Occupational therapy encompasses a wide range of treatments and interventions for both physical and neurological disabilities that might interrupt a childs ability to go about their daily life

While no differences in the risk of HSV or HZ infections were observed between GLP-1RA and SGLT-2i in patients with HbA1c 7%, the significantly increased risk of HSV infections associated with GLP-1RA compared to DPP-4i underscores the need for periodic monitoring